- Home
- MDAI vs PRLD Comparison
MDAI vs PRLD Comparison
Compare MDAI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- PRLD
- Stock Information
- Founded
- MDAI 2013
- PRLD 2016
- Country
- MDAI United States
- PRLD United States
- Employees
- MDAI N/A
- PRLD N/A
- Industry
- MDAI Medical/Dental Instruments
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- MDAI Health Care
- PRLD Health Care
- Exchange
- MDAI Nasdaq
- PRLD Nasdaq
- Market Cap
- MDAI 51.5M
- PRLD 48.6M
- IPO Year
- MDAI N/A
- PRLD 2020
- Fundamental
- Price
- MDAI $2.48
- PRLD $0.81
- Analyst Decision
- MDAI Strong Buy
- PRLD Strong Buy
- Analyst Count
- MDAI 2
- PRLD 2
- Target Price
- MDAI $4.75
- PRLD $4.50
- AVG Volume (30 Days)
- MDAI 503.5K
- PRLD 229.3K
- Earning Date
- MDAI 08-11-2025
- PRLD 08-11-2025
- Dividend Yield
- MDAI N/A
- PRLD N/A
- EPS Growth
- MDAI N/A
- PRLD N/A
- EPS
- MDAI N/A
- PRLD N/A
- Revenue
- MDAI $29,962,000.00
- PRLD $7,000,000.00
- Revenue This Year
- MDAI N/A
- PRLD N/A
- Revenue Next Year
- MDAI $15.14
- PRLD N/A
- P/E Ratio
- MDAI N/A
- PRLD N/A
- Revenue Growth
- MDAI 55.21
- PRLD N/A
- 52 Week Low
- MDAI $0.82
- PRLD $0.61
- 52 Week High
- MDAI $3.25
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- MDAI 71.31
- PRLD 44.61
- Support Level
- MDAI $2.07
- PRLD $0.78
- Resistance Level
- MDAI $2.22
- PRLD $0.89
- Average True Range (ATR)
- MDAI 0.17
- PRLD 0.10
- MACD
- MDAI 0.01
- PRLD -0.02
- Stochastic Oscillator
- MDAI 75.41
- PRLD 17.02
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.